In order to close the research and innovation gap between the European Member States, the Commission has designed the Spreading Excellence and Widening Participation strategy. Measures supported under this strategy will help low R&I performing EU countries to increase their participation in Horizon Europe.
manhei.to@fwo.be
+32 2 550 15 55
In order to close the research and innovation gap between the European Member States, the Commission has designed the Spreading Excellence and Widening Participation strategy. Measures supported under this strategy will help low R&I performing EU countries to increase their participation in Horizon Europe.
There is a wide range of actions that can be used to achieve this objective from enhancing research and innovation capacity, spurring national reforms, facilitating brain circulation, launching measures for promoting excellence to creating new collaborative networks across the EU and supporting the opening of established networks to applicants from widening countries.
The 2023-2024 Work Programme will include four traditional widening instruments in addition to a number of novel elements included in the advancing Europe package agreed by the legislators in March 2019 to create impact on the above mentioned actions:
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.